SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

ASCO 2025, Renal Cancer, kidney cancer, Non-clear cell renal cell carcinoma (non-ccRCC), Ipilimumab, nivolumab, SUNNIFORECAST Trial, Tumor Nephrectomy, tyrosine kinase inhibitors (TKIs), immune ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the session Advancing Perioperative Treatment Options for ...

ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.

ASCO 2025 CA209-8TY trial, phase 2 trial of nivolumab and ipilimumab, stereotactic body radiation therapy, metastatic castration-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors ...

ASCO 2025 HLA class I expression on the tumor immune microenvironment, prostate cancer, Human leukocyte antigen (HLA) class I, T-cell interactions ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

ASCO 2025, urothelial carcinoma (UC), Metastatic Bladder Cancer, Enfortumab Vedotin (EV), Dose Reduction in Metastatic Bladder Cancer, Nectin-4.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

PSMA and Beyond 2025 approved PSMA imaging agents, evolution of PSMA imaging agents, UCSF/UCLA 68Ga-PSMA-11 trial, OSPREY 18F-DCFPyL trial, LIGHTHOUSE 18F-rhPSMA 7.3 trial.

ASCO 2025 Artera's ASCO 2025 first validated MMAI algorithm—used in the ArteraAI Prostate Test shows its AI test may identify which high-risk prostate cancer patients benefit from ARPI, sparing many ...